AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has analysts on the Bullish side this week.

April 17, 2018 - By Clifton Ray

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) LogoInvestors sentiment decreased to 0.9 in Q4 2017. Its down 0.54, from 1.44 in 2017Q3. It worsened, as 29 investors sold AMAG Pharmaceuticals, Inc. shares while 53 reduced holdings. 24 funds opened positions while 50 raised stakes. 37.72 million shares or 5.64% less from 39.98 million shares in 2017Q3 were reported.
Thrivent Fincl For Lutherans has 21,932 shares. One Trading L P owns 8,634 shares. Gsa Cap Prns Llp holds 0.08% or 100,561 shares. Trexquant Invest Limited Partnership invested in 28,940 shares or 0.04% of the stock. Parametric Port Assocs Ltd Llc holds 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 361,806 shares. 642,098 were accumulated by Millennium Mngmt. Bogle Mgmt L P De owns 328,455 shares. Parallax Volatility Advisers Lp invested in 5,376 shares. Falcon Point Capital Ltd Limited Liability Company stated it has 685,237 shares or 1.53% of all its holdings. Gotham Asset Mgmt Ltd holds 0.01% or 73,141 shares. Regions Fin Corporation invested 0% of its portfolio in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Moreover, Piermont Cap has 0.06% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 13,110 shares. California Employees Retirement invested in 84,241 shares or 0% of the stock. California-based Wells Fargo Mn has invested 0% in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG). Moreover, Lsv Asset has 0.02% invested in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) for 1.12M shares.

Since February 23, 2018, it had 0 buys, and 1 sale for $16,016 activity.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Coverage

Among 8 analysts covering AMAG Pharmaceuticals (NASDAQ:AMAG), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. AMAG Pharmaceuticals had 17 analyst reports since October 23, 2017 according to SRatingsIntel. The firm earned “Hold” rating on Thursday, February 1 by Cantor Fitzgerald. The stock has “Hold” rating by Piper Jaffray on Wednesday, February 14. Jefferies downgraded the stock to “Hold” rating in Monday, March 5 report. On Thursday, January 18 the stock rating was maintained by Piper Jaffray with “Hold”. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) earned “Hold” rating by Cantor Fitzgerald on Wednesday, February 14. The firm has “Overweight” rating given on Wednesday, February 28 by Morgan Stanley. The stock of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has “Hold” rating given on Thursday, November 2 by Cantor Fitzgerald. The firm earned “Buy” rating on Thursday, February 15 by Janney Capital. Jefferies maintained the stock with “Buy” rating in Friday, November 3 report. Cantor Fitzgerald maintained the shares of AMAG in report on Tuesday, February 27 with “Hold” rating. Below is a list of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) latest ratings and price target changes.

23/03/2018 Broker: FBR Capital Rating: Hold New Target: $23.0000 Maintain
05/03/2018 Broker: Jefferies Old Rating: Buy New Rating: Hold Downgrade
27/02/2018 Broker: Cowen & Co Rating: Hold New Target: $25.0 Maintain
27/02/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $17.0 Maintain
28/02/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $22 New Target: $24 Maintain
15/02/2018 Broker: Jefferies Rating: Buy New Target: $18.0 Maintain
14/02/2018 Broker: Piper Jaffray Rating: Hold New Target: $18.0 Maintain
15/02/2018 Broker: Cowen & Co Rating: Hold New Target: $20.0
15/02/2018 Broker: Janney Capital Old Rating: Neutral New Rating: Buy Old Target: $45 Upgrade
14/02/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $17.0 Maintain

The stock increased 1.43% or $0.3 during the last trading session, reaching $21.25. About 510,900 shares traded. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has declined 16.25% since April 17, 2017 and is downtrending. It has underperformed by 27.80% the S&P500.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, makes, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. The company has market cap of $724.39 million. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme , an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. It currently has negative earnings. The firm also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.